What Semax costs in the Netherlands

If you are looking for an official Semax price list from a Dutch pharmacy, you will not find one. Semax holds no marketing authorisation from the EMA or the College ter Beoordeling van Geneesmiddelen (CBG-MEB), the Netherlands' national medicines authority^[1]. No authorisation means no regulated price, no reimbursement through the Geneesmiddelenvergoedingssysteem (GVS), and no Dutch pharmacy that can legally dispense it. This article explains what that regulatory gap means in practice, what the grey-market supply chain looks like, and what Dutch readers should know before making any decisions.

Why there is no official Semax price in the Netherlands

The Netherlands operates under the Geneesmiddelenwet (Medicines Act), which prohibits the import, stockpiling, or distribution of any medicine without a licence from the Ministry of Health^[2]. Before a medicine can receive a licence and be priced or reimbursed, it must first clear the authorisation process: either a centralised EMA procedure or a national CBG-MEB procedure. Semax has gone through neither.

Semax is a synthetic heptapeptide derived from the ACTH(4-7) fragment of adrenocorticotropic hormone. It is a licensed prescription nasal spray in Russia, where it has been on the national List of Vital and Essential Drugs since December 2011, with clinical use in ischemic stroke rehabilitation. That Russian authorisation does not travel. It confers no rights, obligations, or recognition in the EU, and the EMA has no record of a Semax application, EPAR, or referral.

The clinical evidence that exists for Semax is largely Russian and largely from the stroke-rehabilitation setting. The most cited controlled trial^[3] enrolled 110 patients across early and late rehabilitation groups and found elevated BDNF levels and improved Barthel index scores in the Semax arms. That is not the kind of evidence package the EMA or CBG-MEB requires for authorisation: a single 110-patient trial in a specific clinical setting, published in a Russian-language journal, with no independent replication, is far short of the full Phase 3 programme a centralised authorisation demands.

The regulatory conclusion for Dutch residents is therefore simple. There is no official Semax price in the Netherlands because there is no official Semax product. Any price you see quoted online is not a Dutch pharmacy price. It is a grey-market research chemical price.

Grey-market pricing: what research chemical suppliers charge

Semax circulates in two distinct product forms outside Russia. The first is the Russian-format nasal spray, a 1% solution typically in a 3 ml dropper bottle, manufactured by domestic Russian producers under Russian pharmaceutical quality standards. The second is a generic research peptide vial, synthesised by custom peptide labs and sold as a "research chemical" with a certificate of analysis.

Neither product type has a published price list that a journalist can cite with confidence, because vendor pricing changes frequently and because citing a specific vendor would amount to a recommendation the editorial team is not in a position to make. What the category looks like, based on the structure of the research chemical market, is a product priced at the lower end of the research peptide range. Semax is a short heptapeptide. Its synthesis cost is considerably lower than longer peptides like semaglutide or tirzepatide. Research chemical suppliers in Europe typically price it in a range that makes it affordable relative to GLP-1 class compounds, but that price tells you nothing about quality, purity, or contamination.

What we can say with confidence: no Dutch regulated pharmacy stocks Semax, no GVS price has been set, and no reimbursement rate exists. If you encounter a price in the Netherlands for Semax, it comes from an unregulated channel.

How Semax pricing compares to other research peptides

Semax is structurally simple by peptide standards. Seven amino acids, a molecular weight of 813.93 g/mol^[4], and a synthesis route that is well-established among the labs that produce it commercially. This makes it relatively inexpensive to manufacture compared to longer or more structurally complex peptides.

GLP-1 class peptides like semaglutide or tirzepatide are 26 to 39 amino acids, require more complex synthesis steps, and command significantly higher prices in the grey market. BPC-157, a 15-residue peptide with its own grey-market following, is typically in a mid-range category. Semax sits below both in synthesis complexity.

The price comparison matters because it affects who buys these products. Lower pricing on Semax means buyers may underestimate the quality stakes. A product sold at a modest price point still carries the same contamination and identity risks as any other unregulated peptide: no batch-release testing under national authority oversight, no pharmacovigilance reporting, and no standardised cold-chain requirements during international shipping.

What no reimbursement means in practice

In the Netherlands, the GVS is the system through which prescribed medicines become reimbursable under the Zorgverzekeringswet (health insurance law). A medicine must first have CBG-MEB or EMA authorisation, then be assessed for cost-effectiveness, before it can enter the GVS. Semax clears none of those steps.

The practical consequence for a Dutch resident interested in Semax is that there is no reimbursement path, no prescription route through a Dutch physician that leads to a dispensed Semax product from a regulated pharmacy, and no legal import route for personal use that bypasses the Geneesmiddelenwet requirements. The law's prohibition on unlicensed medicine import is general. It does not create an individual exception for small personal quantities in the way that some other EU member states handle borderline cases.

This is meaningfully different from the situation with authorised medicines that a patient self-pays for without reimbursement. If Semax were authorised but not reimbursed, Dutch patients could pay privately, buy from a regulated pharmacy, and have quality guarantees. The absence of authorisation removes the quality layer entirely, not just the reimbursement layer.

What Dutch readers should know

The Dutch regulatory position on Semax is not an outlier. Across all seven countries PeptideMethods tracks, Semax holds no marketing authorisation. The EMA register has no Semax entry. The FDA has not approved it. The MHRA has not licensed it. The Russian authorisation is the only pharmaceutical approval that exists, and it does not transfer.

If you are considering Semax for a specific condition, the right starting point is a conversation with a physician or neurologist in the Netherlands who can assess whether the available clinical evidence, which is limited, sparse by Western regulatory standards, and almost entirely confined to the Russian-language stroke rehabilitation literature, is relevant to your situation. A clinician can also tell you whether any licensed, authorised alternative exists for what you are hoping to address.

The research evidence on Semax is real, if limited. The 2005 Eremin study found that Semax modulates serotonergic pathways in rodents. The Gusev 2018 trial found positive signals in stroke rehabilitation. A 2026 review in Frontiers in Aging placed Semax in the category of peptides with "promising preclinical and limited clinical evidence but lacking long-term safety data and systematic validation." None of that evidence translates to an authorised product available in the Netherlands.

Medical disclaimer: this article is for educational and journalistic purposes only. It does not constitute medical advice. Semax is not authorised for human use by the EMA, CBG-MEB, FDA, or MHRA. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any medicine or research chemical.